Search Results - "MOORE, N"

Self-Assembling Multidomain Peptide Nanofibers for Delivery of Bioactive Molecules and Tissue Regeneration by Moore, Amanda N, Hartgerink, Jeffrey D

“…Multidomain peptides (MDPs) are a class of self-assembling peptides that are organized in a β-sheet motif, resulting in a nanofibrous architecture. This…”
Get full text

Antibody-Drug Conjugate-Based Therapeutics: State of the Science by Birrer, Michael J, Moore, Kathleen N, Betella, Ilaria, Bates, Richard C

“…Abstract Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of monoclonal antibodies, directed toward tumor-associated antigens, to…”
Get full text

Bcl-xL is required to protect endothelial cells latently infected with KSHV from virus induced intrinsic apoptosis by Moore, Lyndsey N, Holmes, Daniel L, Sharma, Anjali, Landazuri Vinueza, Joselyn, Lagunoff, Michael

“…Kaposi's Sarcoma herpesvirus (KSHV) is the etiologic agent of Kaposi's Sarcoma (KS), a highly vascularized tumor common in AIDS patients and many countries in…”
Get full text

Assessing discrepancies between previous plate kinematic models of Mesozoic Iberia and their constraints by Barnett‐Moore, N., Hosseinpour, M., Maus, S.

“…Currently, there are several published end‐member plate models that describe the evolution of Iberia during the Mesozoic. We review key geological and…”
Get full text

Steps towards a mechanistic model of global soil nitric oxide emissions: implementation and space based-constraints by Hudman, R. C, Moore, N. E, Mebust, A. K, Martin, R. V, Russell, A. R, Valin, L. C, Cohen, R. C

“…Soils have been identified as a major source (~15%) of global nitrogen oxide (NOx) emissions. Parameterizations of soil NOx emissions (SNOx) commonly used in…”
Get full text

Contaminants of emerging concern in tributaries to the Laurentian Great Lakes: I. Patterns of occurrence by Elliott, Sarah M, Brigham, Mark E, Lee, Kathy E, Banda, Jo A, Choy, Steven J, Gefell, Daniel J, Minarik, Thomas A, Moore, Jeremy N, Jorgenson, Zachary G

“…Human activities introduce a variety of chemicals to the Laurentian Great Lakes including pesticides, pharmaceuticals, flame retardants, plasticizers, and…”
Get full text

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline by Tew, William P, Lacchetti, Christina, Ellis, Annie, Maxian, Kathleen, Banerjee, Susana, Bookman, Michael, Jones, Monica Brown, Lee, Jung-Min, Lheureux, Stéphanie, Liu, Joyce F, Moore, Kathleen N, Muller, Carolyn, Rodriguez, Patricia, Walsh, Christine, Westin, Shannon N, Kohn, Elise C

“…To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal…”
Get full text

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial by Moore, Kathleen N, Secord, Angeles Alvarez, Geller, Melissa A, Miller, David Scott, Cloven, Noelle, Fleming, Gini F, Wahner Hendrickson, Andrea E, Azodi, Masoud, DiSilvestro, Paul, Oza, Amit M, Cristea, Mihaela, Berek, Jonathan S, Chan, John K, Rimel, Bobbie J, Matei, Daniela E, Li, Yong, Sun, Kaiming, Luptakova, Katarina, Matulonis, Ursula A, Monk, Bradley J

“…Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%,…”
Get full text

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) by Moore, Kathleen N, Bookman, Michael, Sehouli, Jalid, Miller, Austin, Anderson, Charles, Scambia, Giovanni, Myers, Tashanna, Taskiran, Cagatay, Robison, Katina, Mäenpää, Johanna, Willmott, Lyndsay, Colombo, Nicoletta, Thomes-Pepin, Jessica, Liontos, Michalis, Gold, Michael A, Garcia, Yolanda, Sharma, Sudarshan K, Darus, Christopher J, Aghajanian, Carol, Okamoto, Aikou, Wu, Xiaohua, Safin, Rustem, Wu, Fan, Molinero, Luciana, Maiya, Vidya, Khor, Victor K, Lin, Yvonne G, Pignata, Sandro

“…To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and…”
Get full text

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial by Naumann, R Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, López-Picazo, Jose M, Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R J, Boni, Valentina, Calvo, Emiliano, Topalian, Suzanne L, Chen, Tian, Soumaoro, Ibrahima, Li, Bin, Gu, Junchen, Zwirtes, Ricardo, Moore, Kathleen N

“…Nivolumab was assessed in patients with virus-associated tumors in the phase I/II CheckMate 358 trial (ClinicalTrials.gov identifier: NCT02488759). We report…”
Get full text

Phenological shifts in lake stratification under climate change by Woolway, R. Iestyn, Sharma, Sapna, Weyhenmeyer, Gesa A., Debolskiy, Andrey, Golub, Malgorzata, Mercado-Bettín, Daniel, Perroud, Marjorie, Stepanenko, Victor, Tan, Zeli, Grant, Luke, Ladwig, Robert, Mesman, Jorrit, Moore, Tadhg N., Shatwell, Tom, Vanderkelen, Inne, Austin, Jay A., DeGasperi, Curtis L., Dokulil, Martin, La Fuente, Sofia, Mackay, Eleanor B., Schladow, S. Geoffrey, Watanabe, Shohei, Marcé, Rafael, Pierson, Don C., Thiery, Wim, Jennings, Eleanor

“…One of the most important physical characteristics driving lifecycle events in lakes is stratification. Already subtle variations in the timing of…”
Get full text

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors by Hassan, Raffit, Blumenschein, Jr, George R, Moore, Kathleen N, Santin, Alessandro D, Kindler, Hedy L, Nemunaitis, John J, Seward, Shelly M, Thomas, Anish, Kim, Stella K, Rajagopalan, Prabhu, Walter, Annette O, Laurent, Dirk, Childs, Barrett H, Sarapa, Nenad, Elbi, Cem, Bendell, Johanna C

“…This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical…”
Get full text

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study by Moore, Kathleen N, Martin, Lainie P, O'Malley, David M, Matulonis, Ursula A, Konner, Jason A, Perez, Raymond P, Bauer, Todd M, Ruiz-Soto, Rodrigo, Birrer, Michael J

“…Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate…”
Get full text

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline by Wright, Alexi A, Bohlke, Kari, Armstrong, Deborah K, Bookman, Michael A, Cliby, William A, Coleman, Robert L, Dizon, Don S, Kash, Joseph J, Meyer, Larissa A, Moore, Kathleen N, Olawaiye, Alexander B, Oldham, Jessica, Salani, Ritu, Sparacio, Dee, Tew, William P, Vergote, Ignace, Edelson, Mitchell I

“…To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian…”
Get full text

Lysosomes, Autophagy, and Hormesis in Cell Physiology, Pathology, and Age-Related Disease by Moore, Michael N.

“…Autophagy has been strongly linked with hormesis, however, it is only relatively recently that the mechanistic basis underlying this association has begun to…”
Get full text

Autophagy as a second level protective process in conferring resistance to environmentally-induced oxidative stress by Moore, Michael N.

“…This conceptual paper addresses the role of lysosomal autophagy in cellular defense against environmentally-induced oxidative stress using a marine mollusc…”
Get full text

PARP inhibitors in the treatment of ovarian cancer: a review by Washington, Christina R., Moore, Kathleen N.

“…This article will review recent changes in the standard of care for olaparib, niraparib, and rucaparib, as well as ongoing trials evaluating this class of…”
Get full text

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline by Wright, Alexi A, Bohlke, Kari, Armstrong, Deborah K, Bookman, Michael A, Cliby, William A, Coleman, Robert L, Dizon, Don S, Kash, Joseph J, Meyer, Larissa A, Moore, Kathleen N, Olawaiye, Alexander B, Oldham, Jessica, Salani, Ritu, Sparacio, Dee, Tew, William P, Vergote, Ignace, Edelson, Mitchell I

“…Abstract Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV…”
Get full text

Ultrafast Spectroscopy of [Mn(CO)3] Complexes: Tuning the Kinetics of Light-Driven CO Release and Solvent Binding by Henke, Wade C, Otolski, Christopher J, Moore, William N. G, Elles, Christopher G, Blakemore, James D

“…Manganese tricarbonyl complexes are promising catalysts for CO2 reduction, but complexes in this family are often photosensitive and decompose rapidly upon…”
Get full text

Interstitial lung disease in patients with common variable immunodeficiency disorders: several different pathologies? by Patel, S., Anzilotti, C., Lucas, M., Moore, N., Chapel, H.

“…Summary Various reports of disease‐related lung pathologies in common variable immunodeficiency disorder (CVID) patients have been published, with differing…”
Get full text